Form 8-K - Current report:
SEC Accession No. 0000950170-25-057337
Filing Date
2025-04-23
Accepted
2025-04-23 16:05:59
Documents
13
Period of Report
2025-04-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20250423.htm   iXBRL 8-K 44446
2 EX-99.1 vktx-ex99_1.htm EX-99.1 209704
3 GRAPHIC img201808844_0.jpg GRAPHIC 13142
  Complete submission text file 0000950170-25-057337.txt   402843

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250423.xsd EX-101.SCH 25063
15 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250423_htm.xml XML 4762
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 25861427
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)